Acute toxicity of second generation HIV protease-inhibitors in combination with radiotherapy: a retrospective case series

Table 2 Baseline data: patients not receiving concurrent protease inhibitor

#	Cancer diagnosis	Age	Concurrent systemic therapy	Baseline CD4	Non-PI HIV regimen
1	SCC, cervix T4N1M0, stage IVa	29	cisplatin	189	None
2	SCC, cervix, stage IIb	34	cisplatin	189	None
3	Cholangiocarcinoma, abdomen pT3N1M0	53	xeloda	300	efavirenz, emtricitabine, tenofovir
4	Adenocarcinoma, prostate TXNXM1, stage IV	48	None	399	None
5	Meningioma, CNS	46	None	408	None
6	Adenocarcinoma, prostate cT1cNXM0, GS	62	androgen	1047	None
	3+4, PSA 20.6, stage II		deprivation
7	NSCLC, brain met, stage IV	57	None	NR	None
8a	DLBCL, brain met, stage IV	46	None	214	efavirenz, emtricitabine, tenofovir
8b	DLBCL, brain met recurrence, stage IV	46	None	214	efavirenz, emtricitabine, tenofovir
8c	DLBCL, testicular met, stage IV	46	None	214	efavirenz, emtricitabine, tenofovir
9	Adenocarcinoma, prostate cT2aNXM0, GS	61	None	150	efavirenz, emtricitabine, tenofovir
	3+4, PSA 1.1, stage II
10	SCC, cervix, stage IIIb	57	cisplatin	116	None
11	SCC, anal	49	mitomycin C and xeloda	450	efavirenz, emtricitabine, tenofovir

Patients are uniquely identified by numbers, repeated treatments on a patient are distinguished by a letter after the number.
NHL = non-Hodgkin lymphoma, DLBCL = diffuse large B-cell lymphoma
cT = clinical tumor, pT = pathological tumor, GS = Gleason score, PSA = prostate specific antigen
NR = not reported

ISSN: 1748-717X